Reduced Incidence of Aortic Dissection in Patients With Type 2 Diabetes Treated With Sodium Glucose Transporter 2 Inhibitors
Journal of the American Heart Association · 2025
DOI: 10.1161/jaha.124.040260 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Chi-Jung Chung und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health, College of Public Health China Medical University Taichung City Taiwan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Aortic Dissection, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Inhibitors for sodium‐glucose transport protein 2 (SGLT2) are being used widely in recent years to treat patients with type 2 diabetes (T2D). Studies demonstrated that SGLT2 inhibitors exhibit protective effect for certain cardiovascular diseases. However, no study has explored the effect of SGLT2 inhibitors on risk of aortic dissection in patients with T2D.
Methods
We extracted and retrospectively analyzed the data of all patients with T2D from Taiwan National Health Institution databases between May 1, 2016, and December 31, 2021. Patients with T2D taking DPP4 (dipeptidyl peptidase 4) inhibitors were included for comparison to exclude glucose lowering effect on aortic dissection. In this cohort, 242 563 patients received SGLT2 inhibitors (T2D‐SGLT2i), and 376 062 patients received DPP4 inhibitors (T2D‐DPP4i). The inverse probability of treatment weighting statistical method was performed, which avoids sample loss due to matching. The hazard ratios (HRs) and 95% CIs for these patients with T2D were calculated using multivariate Cox models to approximate the associations.
Results
The overall aortic dissection incidence per 100 000 patient‐years was 14.83 for patients with T2D‐SGLT2i and 29.56 for patients with T2D‐DPP4i. Patients with T2D‐SGLT2i were associated with a lower risk of aortic dissection as compared with patients with T2D‐DPP4i after the adjustment of potential risk factors and comorbidity. Subgroup analysis indicated that use of SGLT2 inhibitor lowers the risk of aortic dissection in some subgroups of patients with T2D.
Conclusions
Our study suggested that use of SGLT2 inhibitors correlated with lower risk of aortic dissection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Public Health, College of Public Health China Medical University Taichung City Taiwan.
- Department of Medical Research China Medical University Hospital Taichung City Taiwan.
- Department of Surgery, School of Medicine, College of Medicine Taipei Medical University Taipei City Taiwan.
- Division of Cardiovascular Surgery, Department of Surgery, Wan Fang Hospital Taipei Medical University Taipei City Taiwan.
- Division of Nephrology, Department of Medicine Taichung Veterans General Hospital Taichung Taiwan.
- PhD Program in Translational Medicine National Chung Hsing University Taichung Taiwan.
ORCID-Profile: Hsin-Ying Lu, Mu-Chi Chung, Laing-You Wu, Li-Kuo Kuo, Chih-Pin Chuu
Zitieren
APA
Chung, C. J., Lu, H. Y., Chung, M. C., Wu, L. Y., Huo, C., Kuo, L. K., Liu, C. C., & Chuu, C. P. (2025). Reduced Incidence of Aortic Dissection in Patients With Type 2 Diabetes Treated With Sodium Glucose Transporter 2 Inhibitors. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.040260
Vancouver
Chung CJ, Lu HY, Chung MC, Wu LY, Huo C, Kuo LK, et al. Reduced Incidence of Aortic Dissection in Patients With Type 2 Diabetes Treated With Sodium Glucose Transporter 2 Inhibitors. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.040260
BibTeX
@article{Chung2025,
author = {Chung, Chi-Jung and Lu, Hsin-Ying and Chung, Mu-Chi and Wu, Laing-You and Huo, Chieh and Kuo, Li-Kuo and Liu, Chun-Chieh and Chuu, Chih-Pin},
title = {Reduced Incidence of Aortic Dissection in Patients With Type 2 Diabetes Treated With Sodium Glucose Transporter 2 Inhibitors},
journal = {Journal of the American Heart Association},
year = {2025},
doi = {10.1161/jaha.124.040260}
}
EUVIMED